Inclusion Body Myositis: Update on the Diagnostic and Therapeutic Landscape

Overview

Journal Front Neurol

Specialty Neurology

Date 2022 Oct 14

PMID 36237625

Authors

Elie Naddaf

Affiliations

Soon will be listed here.

Abstract

Inclusion body myositis (IBM) is a progressive muscle disease affecting patients over the age of 40, with distinctive clinical and histopathological features. The typical clinical phenotype is characterized by prominent involvement of deep finger flexors and quadriceps muscles. Less common presentations include isolated dysphagia, asymptomatic hyper-CKemia, and axial or limb weakness beyond the typical pattern. IBM is associated with marked morbidity as majority of patients eventually become wheelchair dependent with limited use of their hands and marked dysphagia. Furthermore, IBM mildly affects longevity with aspiration pneumonia and respiratory complications being the most common cause of death. On muscle biopsy, IBM is characterized by a peculiar combination of endomysial inflammation, rimmed vacuoles, and protein aggregation. These histopathological features are reflective of the complexity of underlying disease mechanisms. No pharmacological treatment is yet available for IBM. Monitoring for swallowing and respiratory complications, exercise, and addressing mobility issues are the mainstay of management. Further research is needed to better understand disease pathogenesis and identify novel therapeutic targets.

Citing Articles

Inclusion Body Myositis: A case report on navigating diagnostic challenges.

Al Sharji M, Al Busaidi S, Al Jahdhami S, Jawa Z, Farhan H, Al Alawi A Sultan Qaboos Univ Med J. 2024; 24(4):593-598.

PMID: 39634801 PMC: 11614014. DOI: 10.18295/squmj.6.2024.039.

Whole-body-electro-myostimulation for the care of inclusion body myositis-A case report.

Freitag N, Dragutinovic B, Notbohm H, Filipovic A, Schiffer T, Bloch W Clin Case Rep. 2024; 12(11):e9539.

PMID: 39479585 PMC: 11522995. DOI: 10.1002/ccr3.9539.

Modeling NK-cell lymphoma in mice reveals its cell-of-origin and microenvironmental changes and identifies therapeutic targets.

Koya J, Tanigawa T, Mizuno K, Kim H, Ito Y, Yuasa M Nat Commun. 2024; 15(1):9106.

PMID: 39438472 PMC: 11496546. DOI: 10.1038/s41467-024-53376-1.

Features of Swallowing Function in Sporadic Inclusion Body Myositis: Preliminary Evidence Using Well-Tested Assessment Frameworks.

Ambrocio K, Aggarwal R, Lacomis D, Zhang X, Garand K Am J Speech Lang Pathol. 2024; 33(6):2793-2804.

PMID: 39392897 PMC: 11546978. DOI: 10.1044/2024_AJSLP-24-00061.

Quantitative muscle MRI in sporadic inclusion body myositis (sIBM): A prospective cohort study.

Schlaffke L, Rehmann R, Froeling M, Guttsches A, Vorgerd M, Enax-Krumova E J Neuromuscul Dis. 2024; 11(5):997-1009.

PMID: 39031378 PMC: 11380292. DOI: 10.3233/JND-240053.

References

Nicolau S, Liewluck T, Milone M . Myopathies with finger flexor weakness: Not only inclusion-body myositis. Muscle Nerve. 2020; 62(4):445-454. DOI: 10.1002/mus.26914. View

Walter M, Lochmuller H, Toepfer M, Schlotter B, Reilich P, Schroder M . High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J Neurol. 2000; 247(1):22-8. DOI: 10.1007/s004150050005. View

Mastaglia F, Needham M, Scott A, James I, Zilko P, Day T . Sporadic inclusion body myositis: HLA-DRB1 allele interactions influence disease risk and clinical phenotype. Neuromuscul Disord. 2009; 19(11):763-5. DOI: 10.1016/j.nmd.2009.07.015. View

Lloyd T, Mammen A, Amato A, Weiss M, Needham M, Greenberg S . Evaluation and construction of diagnostic criteria for inclusion body myositis. Neurology. 2014; 83(5):426-33. PMC: 4132572. DOI: 10.1212/WNL.0000000000000642. View

Pandya J, Fasth A, Zong M, Arnardottir S, Dani L, Lindroos E . Expanded T cell receptor Vβ-restricted T cells from patients with sporadic inclusion body myositis are proinflammatory and cytotoxic CD28null T cells. Arthritis Rheum. 2010; 62(11):3457-66. DOI: 10.1002/art.27665. View

Zanusso G, Vattemi G, Ferrari S, Tabaton M, Pecini E, Cavallaro T . Increased expression of the normal cellular isoform of prion protein in inclusion-body myositis, inflammatory myopathies and denervation atrophy. Brain Pathol. 2001; 11(2):182-9. PMC: 8098622. DOI: 10.1111/j.1750-3639.2001.tb00390.x. View

Lloyd T, Christopher-Stine L, Pinal-Fernandez I, Tiniakou E, Petri M, Baer A . Cytosolic 5'-Nucleotidase 1A As a Target of Circulating Autoantibodies in Autoimmune Diseases. Arthritis Care Res (Hoboken). 2015; 68(1):66-71. PMC: 4887848. DOI: 10.1002/acr.22600. View

Rothwell S, Cooper R, Lundberg I, Gregersen P, Hanna M, Machado P . Immune-Array Analysis in Sporadic Inclusion Body Myositis Reveals HLA-DRB1 Amino Acid Heterogeneity Across the Myositis Spectrum. Arthritis Rheumatol. 2017; 69(5):1090-1099. PMC: 5516174. DOI: 10.1002/art.40045. View

Mendell J, Sahenk Z, Gales T, Paul L . Amyloid filaments in inclusion body myositis. Novel findings provide insight into nature of filaments. Arch Neurol. 1991; 48(12):1229-34. DOI: 10.1001/archneur.1991.00530240033013. View

10.

Rose M . 188th ENMC International Workshop: Inclusion Body Myositis, 2-4 December 2011, Naarden, The Netherlands. Neuromuscul Disord. 2013; 23(12):1044-55. DOI: 10.1016/j.nmd.2013.08.007. View

11.

Herbert M, Stammen-Vogelzangs J, Verbeek M, Rietveld A, Lundberg I, Chinoy H . Disease specificity of autoantibodies to cytosolic 5'-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases. Ann Rheum Dis. 2015; 75(4):696-701. PMC: 4699257. DOI: 10.1136/annrheumdis-2014-206691. View

12.

Custer S, Neumann M, Lu H, Wright A, Taylor J . Transgenic mice expressing mutant forms VCP/p97 recapitulate the full spectrum of IBMPFD including degeneration in muscle, brain and bone. Hum Mol Genet. 2010; 19(9):1741-55. DOI: 10.1093/hmg/ddq050. View

13.

Jorgensen A, Aagaard P, Frandsen U, Boyle E, Diederichsen L . Blood-flow restricted resistance training in patients with sporadic inclusion body myositis: a randomized controlled trial. Scand J Rheumatol. 2018; 47(5):400-409. DOI: 10.1080/03009742.2017.1423109. View

14.

Nalbandian A, Llewellyn K, Badadani M, Yin H, Nguyen C, Katheria V . A progressive translational mouse model of human valosin-containing protein disease: the VCP(R155H/+) mouse. Muscle Nerve. 2012; 47(2):260-70. PMC: 3556223. DOI: 10.1002/mus.23522. View

15.

Pluk H, van Hoeve B, van Dooren S, Stammen-Vogelzangs J, van der Heijden A, Schelhaas H . Autoantibodies to cytosolic 5'-nucleotidase 1A in inclusion body myositis. Ann Neurol. 2013; 73(3):397-407. DOI: 10.1002/ana.23822. View

16.

Hargitai J, Lewis H, Boros I, Racz T, Fiser A, Kurucz I . Bimoclomol, a heat shock protein co-inducer, acts by the prolonged activation of heat shock factor-1. Biochem Biophys Res Commun. 2003; 307(3):689-95. DOI: 10.1016/s0006-291x(03)01254-3. View

17.

Kazamel M, Sorenson E, Milone M . Clinical and Electrophysiological Findings in Hereditary Inclusion Body Myopathy Compared With Sporadic Inclusion Body Myositis. J Clin Neuromuscul Dis. 2016; 17(4):190-6. DOI: 10.1097/CND.0000000000000113. View

18.

Dalakas M, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K . Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology. 1997; 48(3):712-6. DOI: 10.1212/wnl.48.3.712. View

19.

Cox F, Verschuuren J, Verbist B, Niks E, Wintzen A, Badrising U . Detecting dysphagia in inclusion body myositis. J Neurol. 2009; 256(12):2009-13. PMC: 2780610. DOI: 10.1007/s00415-009-5229-9. View

20.

Goyal N, Coulis G, Duarte J, Farahat P, Mannaa A, Cauchii J . Immunophenotyping of Inclusion Body Myositis Blood T and NK Cells. Neurology. 2022; 98(13):e1374-e1383. PMC: 8967422. DOI: 10.1212/WNL.0000000000200013. View